Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on track
Enrollment continues in JANX007, JANX014, and JANX011 trials, with JANX013 still set to start clinical testing in the second half of 2026.
SEC filing
Latest
2 stories